Ropinirole

Ropinirol (also spelled ropinirole) is a dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome (RLS). It acts on dopamine receptors in the brain to mimic the effects of dopamine, a neurotransmitter that is progressively depleted in Parkinson's disease and whose dysregulation is believed to contribute to the sensory disturbances of restless legs syndrome. Ropinirol is available in both immediate-release and prolonged-release tablet formulations, providing flexible dosing options for different patient needs.

Mechanism of Action

Ropinirol is a selective, non-ergoline dopamine D2 and D3 receptor agonist. In Parkinson's disease, degeneration of dopaminergic neurons in the substantia nigra leads to dopamine deficiency in the basal ganglia, producing the characteristic motor features of tremor, rigidity, bradykinesia, and postural instability. Ropinirol compensates for this deficiency by directly stimulating dopamine receptors, helping to restore more coordinated and fluid movement. Because it does not require conversion from levodopa, its effects are not dependent on remaining dopamine-producing neurons, making it particularly valuable as those neurons continue to decline.

Use in Parkinson's Disease and RLS

In early Parkinson's disease, ropinirol may be used as monotherapy to delay the need for levodopa, thereby deferring the onset of levodopa-related motor complications such as dyskinesias and motor fluctuations. In more advanced disease, it is used in combination with levodopa to allow lower levodopa doses. For restless legs syndrome, ropinirol at lower doses effectively reduces the uncomfortable urge to move the legs, involuntary leg movements, and the sleep disturbance they cause. Treatment in RLS typically begins in the evening and involves gradual dose titration over several weeks.

Tolerability and Monitoring

Ropinirol is generally well tolerated when doses are increased gradually. Nausea is the most common early side effect and usually resolves with time. Impulse control disorders represent the most clinically significant risk, requiring regular monitoring throughout treatment.

Parkinson's Disease Dosing

Ropinirole for Parkinson's disease is started at a low dose and increased gradually. Immediate-release tablets typically begin at 0.25 mg three times daily, increasing at weekly intervals. The full therapeutic dose is usually reached over 4 to 8 weeks. Prolonged-release ropinirole follows a similar titration starting at 2 mg once daily. Take with food where possible to reduce nausea during the titration phase.

Restless Legs Syndrome

For restless legs syndrome, take ropinirole once daily, 1 to 3 hours before bedtime. Starting dose is 0.25 mg, increasing over two weeks to 1 mg if needed, up to a maximum of 4 mg per day. Do not stop ropinirole abruptly, taper the dose gradually over at least one week to prevent withdrawal effects.

For Parkinson's disease, immediate-release ropinirol starts at 0.25 mg three times daily. The dose is increased by 0.75 mg per day each week for 4 weeks, then by up to 3 mg per day per week thereafter, up to a maximum of 24 mg/day. Prolonged-release formulations begin at 2 mg once daily, increased by 2 mg increments at weekly intervals, also to a maximum of 24 mg/day. For RLS, the maximum dose is 4 mg/day. Patients with severe renal impairment (creatinine clearance below 30 mL/min) should be monitored carefully; dose adjustments may be required. In patients taking ciprofloxacin, ropinirol exposure increases significantly and dose reduction is often necessary. Smokers who quit during treatment may need dose reduction due to increased ropinirol levels following cessation of CYP1A2 induction. Elderly patients should be titrated cautiously.

Common Side Effects

• Nausea, particularly at initiation or following dose increases
• Dizziness and postural hypotension
• Somnolence and daytime sleepiness
• Hallucinations (more common in the elderly)
• Headache
• Peripheral oedema (leg and ankle swelling)
• Fatigue and general weakness
• Confusion and disorientation, especially in older patients

Serious Side Effects

• Impulse control disorders: pathological gambling, compulsive sexual behaviour, binge eating - requires urgent dose review
• Sudden sleep attacks: sleeping without warning, a risk for drivers
• Dopamine agonist withdrawal syndrome: severe anxiety, depression, and pain on abrupt cessation
• Syncope: sudden loss of consciousness, particularly early in treatment or after dose increases
• Neuroleptic malignant syndrome-like reaction if abruptly discontinued
• Hallucinations requiring hospitalisation in vulnerable patients

Impulse Control Disorders

Patients treated with ropinirol must be monitored regularly for the development of impulse control disorders. These behaviours - including compulsive gambling, uncontrolled spending, hypersexuality, and binge eating - can emerge at any point in treatment and may be unrecognised by the patient as problematic. Carers should be involved in monitoring. Dose reduction or discontinuation is often required if impulse control disorders develop. Patients should be warned about these risks before starting treatment and at each follow-up appointment.

Somnolence and Driving

Ropinirol causes somnolence in a significant proportion of patients. Episodes of sudden onset sleep, sometimes without preceding drowsiness or warning signs, have been reported. Patients should be counselled about the risk of falling asleep while driving or operating machinery. Those who experience such episodes must refrain from driving. Concomitant use of sedative medicines or alcohol potentiates drowsiness. The prescriber should regularly reassess the patient's fitness to drive throughout treatment.

Ropinirol should be used with caution in patients with severe cardiovascular disease, as hypotension can worsen ischaemic symptoms. Blood pressure monitoring at the start of treatment is advisable. The medicine should be avoided in pregnancy and breastfeeding unless clearly necessary.

• Known hypersensitivity to ropinirole or to any excipient
• Severe hepatic impairment
• Pregnancy (unless clearly necessary and no safer alternative is available)
• Breastfeeding (may inhibit lactation; passes into breast milk)
• Concurrent use of antipsychotics that block dopamine receptors (reduces efficacy; may worsen Parkinson's symptoms)
• Severe renal impairment requiring dialysis
• History of impulse control disorder unless risk-benefit assessment strongly favours treatment
• Concomitant use of ciprofloxacin at high doses without appropriate dose adjustment of ropinirol